Trending...
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Boston Industrial Solutions Introduces Personalized Printing Training
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on The PennZone
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
- Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- A New Tale Band Makes 9/11 Tribute Song "The Twins" Free for Ceremonies and School Programs